Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG2417 in Bipolar I Depression
NCT00322764Phase 2Completed
- Sponsor
- Repligen Corporation
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of uridine in bipolar I disorder, sponsored by Repligen Corporation. Started Mar 2006; status: completed.
02
Drugs
uridine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00322764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322764.